Back to Pharmaceutical Members (PH)
Bioscience Company Member
Organization Overview
Higher Medicine (HM) aims to usher in a new age of functional cure for Friedreich’s Ataxia (FA) patients by repurposing clinically-validated p38 MAP Kinase inhibitors and other safe small molecules. HM also aims to establish leadership in the budding field of epigenetic therapy by developing a novel platform to cure FA, Fragile-X syndrome, Alzheimer’s, certain cancers, and other serious conditions sharing the DNA repeat expansion mechanism. We seek to break frontiers, as done in Cystic Fibrosis, through scientific leaps comparable to the rise of mRNA or CRISPR technologies.
HM is led by experienced industry veterans trained at blue-chip institutions such as Novartis, AstraZeneca, and McKinsey, and has several licensing option agreements in place that are ready to execute upon financing. We are raising $2 million to launch lead clinical programs for rapid inflection towards a $150+ million valuation by 2027.
HM is led by experienced industry veterans trained at blue-chip institutions such as Novartis, AstraZeneca, and McKinsey, and has several licensing option agreements in place that are ready to execute upon financing. We are raising $2 million to launch lead clinical programs for rapid inflection towards a $150+ million valuation by 2027.
Bioscience Company Member